The ascendancy of Viagra and its impact on the medicinal landscape presents a complicated question for shareholders. While the first sales data were astounding, the intellectual property has expired, leading to a flood of copycat alternatives that are eroding earnings. Furthermore, the sector is facing challenges related to demographic trends an… Read More